ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia, a leading cause of mental and physical disability in elderly people. Current pharmaceutical management of AD oers only modest short-term symptomatic relief and does not satisfactorily consider the magnitude of the disease burden on patients and the community as a whole. Acetylcholinesterase (AChE) inhibitors or glutamate receptor antagonists are typically used to manage the behavioural and psychological symptoms of AD, but there is limited evidence on their ecacy for patients beyond the rst 6-12 months (Madhusoodanan and Ting, 2014) (see Chapter 52).
